Back to the Future: Porting Legacy Assays to Microfluidic Cartridges
Richard Spero, CEO, Redbud Labs
Despite booming investment, the use of microfluidic and sample-to-answer platforms is still dwarfed by traditional molecular tests and immunoassays. Imagine being able to rapidly port this vast back-catalogue of assays to a cartridge-based format. We report on the development of modular microfluidic chips that can readily implement a wide range of legacy assays without degradation in performance, from isothermal amplification to nucleic acid purification.
|
|